Health Canada recently issued the first certificates of supplementary protection (CSPs) against the following approvals:

  • neisseria meningitidis grp B recombinant lipoprotein 2086 sub-family A/neisseria meningitidis group B recombinant lipoprotein 2086 sub-family B (Pfizer's Trumenba);
  • letermovir (Merck's Prevymis); and
  • guselkumab (Tremfya).(1)

In addition, on April 1 2018 the CSP application fee was increased to C$9,192.

For further information on this topic please contact Katie Lee at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email ( The Smart & Biggar/Fetherstonhaugh website can be accessed at


(1) See Register of Certificates of Supplementary Protection.

This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.